Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes.

Trial Profile

Effect on Glycemic Control of Liraglutide in Combination With Rosiglitazone Plus Metformin Versus Rosiglitazone Plus Metformin in Subjects With Type 2 Diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Liraglutide (Primary) ; Metformin; Rosiglitazone
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms LEAD-4
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 14 Jul 2016 Results of a meta-analysis in African-American/black people with T2DM from seven phase III trials (NCT00395746, NCT00614120, NCT00294723, NCT00333151, NCT00331851, NCT00518882 and NCT00700817), published in the Diabetic Medicine
    • 25 Jun 2010 Outcomes from a pooled anlaysis of the 6 LEAD trials were reported at the 70th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top